Analyst picks & changes

Celtrix Pharmaceuticals Inc.

(CTRX)

Oppenheimer & Co. analyst Jeffrey Casdin rated CTRX a "buy" and added it to OpCo's "Recommended List." When CTRX was spun off

Read the full 265 word article

How to gain access

Continue reading with a
two-week free trial.